MedPath

Prevention of Oxaliplatin-induced Nerve Damage in the Body's Extremities

Not Applicable
Recruiting
Conditions
Peripheral Neuropathy
Colorectal Cancer
Interventions
Dietary Supplement: Fish oil
Dietary Supplement: Corn oil
Registration Number
NCT05404230
Lead Sponsor
Vejle Hospital
Brief Summary

The purpose of this study is to examine the effect of supplementary polyunsaturated fatty acids on nerve damage in the body's extremitites of patients treated with oxaliplatin containing chemotherapy after surgery for colorectal cancer.

Detailed Description

The primary objective of the present study is to examine if a high dosage of n-3 PUFA reduces the incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN) 8 months after adjuvant oxaliplatin following surgery for high-risk colorectal cancer.

An additional aim is to investigate whether n-3 PUFAs have an effect on nutritional status, cognition and mental status. Inflammatory mechanisms and biomarkers of CIPN in skin biopsies and in blood will be explored.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Histopathologically verified adenocarcinoma of the colon or rectum and planned standard adjuvant treatment with capecitabine in combination with oxaliplatin.
  • ECOG performance status 0-2 (measurement of a patient's function in terms of self-care, daily activity and physical ability.
  • Written and orally informed informed consent
Exclusion Criteria
  • Inability to speak, read, and understand Danish.
  • Previous treatment with neurotoxic chemotherapy.
  • Neurological (including neuropathy) or psychiatric disorders, diabetes or other significant medical conditions.
  • Alcohol or drug abuse.
  • Sensory disturbances in the feet
  • Spinal stenosis.
  • Vascular disease (Fontaine grade II or more).
  • Known allergy to fish, fish oil or corn oil
  • Fertile patients not willing to use effective methods of contraception during treatment or abstinence.
  • Daily intake of oil supplements and not willing to stop during the trial period.
  • Lack of consent to skin biopsy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Fish oilFish oil4 capsules containing n-3 poly unsaturated fatty acids (EPA and DHA) with a total concentration of 3 g per day. 4 capsules per day for 8 months
Corn oilCorn oil4 capsules containing n-6 poly unsaturated fatty acids in a total concentration of 2 g per day. 4 capsules per day for 8 months. Corn oil is regularly used in the kitchen and the daily dose in the study is the equivalent of adding an extra spoon of food oil when cooking. It has no known effect on the parameters we want to examine.
Primary Outcome Measures
NameTimeMethod
Incidence of chemotherapy induced peripheral neuropathy (CIPN) 8 months after start of adjuvant chemotherapy8 months after start of adjuvant chemotherapy

Number of patients who meet the criteria for CIPN: relevant symptoms evaluated by a medical doctor, incl one of the following: abnormal vibration test or, abnormal nerve conduction test by DPN check device or, abnormal pinprick test or, abnormal skin biopsy.

Secondary Outcome Measures
NameTimeMethod
Change in severity of CIPN from baseline to 8 months after start of adjuvant chemotherapy according to the EORCT QLQ-CIPN 20 questionnaire8 months after start of adjuvant chemotherapy

EORCT QLQ-CIPN 20 = the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy Induced Peripheral Neuropathy

Intensity of CIPN-related neuropathic pain 8 months after adjuvant chemotherapy according to the Numeric Rating Scale (NRS)8 months after start of adjuvant chemotherapy

Average over the past 24 hours measured by NRS (scale from 0-10 with 0=no pain and 10=worst pain imaginable)

Trial Locations

Locations (1)

Deparment of Oncology, Vejle Hospital

🇩🇰

Vejle, Denmark

© Copyright 2025. All Rights Reserved by MedPath